1

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 3/A

NEUROCRINE BIOSCIENCES INC Form 3/A February 05, 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

#### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Gano Kyle			eporting	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [NBIX]		
	(Last)	(First)	(Middle)	02/05/2015	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)	
	NEUROCRII INC., 1278		· · · · ·		(Check all applicable)	01/28/2013	
	REAL	ULLUA					

(Street)

### SAN DIEGO, CAÂ 92130

(State)

(City)

1.

(I

(eng)	(Build)	( <b>2</b> - <b>P</b> )	Table I - Noll-I
.Title of Sec Instr. 4)	urity		2. Amount of Secu Beneficially Owne (Instr. 4)

(Zip)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

**OMB APPROVAL** 

10% Owner Director \_X\_\_Officer Other (give title below) (specify below) Chief Business Dev Officer

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting Person \_ Form filed by More than One

# Reporting Person

#### Table I - Non-Derivative Securities Beneficially Owned

urities 3. ed Ownership Form: Direct (D) or Indirect (I)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

SEC 1473 (7-02)

(Instr. 5)

### Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 3/A

				Shares	or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	(1)	05/11/2017	Common stock	45,000 <u>(2)</u> \$ 2.5	9 D	Â

### **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Gano Kyle NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL SAN DIEGO, CA 92130	Â	Â	Chief Business Dev Officer	Â		
Signatures						
Darin Lippolt, By Power of Attorney	02/05/2	.015				

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vested in thirty-six equal monthly installments beginning June 11, 2010.

(2) The total number of shares represented by this Employee Stock Option were under-reported by 5,000 shares in the Reporting Person's Form 3.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.